The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Open accessAbstract
Multidrug-resistant Acinetobacter baumannii has emerged as a significant clinical problem worldwide and colistin is being used increasingly as “salvage” therapy. MICs of colistin against A. baumannii indicate its significant activity. However, resistance to colistin in A. baumannii has been reported recently. Clonotypes of 16 clinical A. baumannii isolates and ATCC 19606 were determined by pulsed-field gel electrophoresis (PFGE), and colistin MICs were measured. The time-kill kinetics of colistin against A. baumannii ATCC 19606 and clinical isolate 6 were investigated, and population analysis profiles (PAPs) were conducted. Resistance development was investigated by serial passaging with or without exposure to colistin. Five different PFGE banding patterns were found in the clinical isolates. MICs of colistin against all isolates were within 0.25 to 2 μg/ml. Colistin showed early concentration-dependent killing, but bacterial regrowth was observed at 24 h. PAPs revealed that heteroresistance to colistin occurred in 15 of the 16 clinical isolates. Subpopulations (<0.1% from inocula of 10 8 to 10 9 CFU/ml) of ATCC 19606, and most clinical isolates grew in the presence of colistin 3 to 10 μg/ml. Four successive passages of ATCC 19606 in broth containing colistin (up to 200 μg/ml) substantially increased the proportion of the resistant subpopulations able to grow in the presence of colistin at 10 μg/ml from 0.000023 to 100%; even after 16 passages in colistin-free broth, the proportion only decreased to 2.1%. This represents the first demonstration of heterogeneous colistin-resistant A. baumannii in “colistin-susceptible” clinical isolates. Our findings give a strong warning that colistin-resistant A. baumannii may be observed more frequently due to potential suboptimal dosage regimens recommended in the product information of some products of colistin methanesulfonate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H., & Swaminathan, B. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.9.2233-2239.1995 · Cited by 8,204
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984 · cited 1×
“Most knowledge on heteroresistance to antibiotics concerns vancomycin in Staphylococcus aureus (13, 14).”
BackgroundFalagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
Hiramatsu, K. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00091-3 · Cited by 759
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Self-citationPolymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria
Evans, M. E., Feola, D. J., & Rapp, R. P. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18426 · Cited by 544
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Self-citationCorbella, X., Montero, A., Pujol, M., Domínguez, M. A., Ayats, J., Argerich, M. J., Garrigosa, F., Ariza, J., & Gudiol, F. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.11.4086-4095.2000 · Cited by 348
Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment
Cisneros, J. M., & Rodríguez-Baño, J. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00487.x · Cited by 322
Livermore, D. M. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1004.x · Cited by 314
Michalopoulos, A. S., Tsiodras, S., Rellos, K., Mentzelopoulos, S., & Falagas, M. E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01043.x · Cited by 292
Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians
Jain, R., & Danziger, L. H. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d592 · Cited by 219
Li, J., Rayner, C. R., Nation, R. L., Deans, R., Boots, R. J., Widdecombe, N., Douglas, A., & Lipman, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4814-4815.2005 · Cited by 133
Self-citationArroyo, L. A. R., García-Curiel, A., Pachón-Ibáñez, M. E., Llanos, A. C., Ruiz, M. T., Pachón, J., & Aznar, J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.2.903-905.2005 · Cited by 130
Increasing threat of Gram-negative bacteria
WATERER, G. W., & Wunderink, R. G. (2001) · Critical Care Medicine · doi:10.1097/00003246-200104001-00004 · Cited by 112
Selection of Aminoglycoside-Resistant Variants of Pseudomonas aeruginosa in an in Vivo Model
Gerber, A., Vastola, A. P., Brandel, J., et al. (1982) · The Journal of Infectious Diseases · doi:10.1093/infdis/146.5.691 · Cited by 108
The threat from the pink corner
Livermore, D. M. (2003) · Annals of Medicine · doi:10.1080/07853890310001609 · Cited by 92
Serological and molecular evidence of Rickettsia helvetica in Denmark
Nielsen, H., Fournier, P., Pedersen, I. S., Krarup, H. B., Ejlertsen, T., & Raoult, D. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410020776 · Cited by 72
Heteroresistance to carbapenems in Acinetobacter baumannii
Pournaras, S., Ikonomidis, A., Markogiannakis, A., Maniatis, A. N., & Tsakris, A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki115 · Cited by 57
Hetero-resistance: an under-recognised confounder in diagnosis and therapy?
Editors, T. (2001) · Journal of Medical Microbiology · doi:10.1099/0022-1317-50-12-1018 · Cited by 56
Cited by
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii
Dijkshoorn, L., Nemec, A., & Seifert, H. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1789 · Cited by 1,828
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
Olaitan, A. O., Morand, S., & Rolain, J.-M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00643 · Cited by 1,395
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
Metadata
- Authors
- Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-09
- Volume
- 50
- Issue
- 9
- Pages
- 2946-2950
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1971252925
- Cited by
- 548
- References
- 24
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.